Four selected reports cover randomized trials in erythropoietic protoporphyria (EPP), an observational EPP cohort, combination treatment in vitiligo, and an exploratory stroke study. This is a selected overview, not a completed systematic review.1234
Bottom line from this bounded source set
The EPP trials reported longer pain-free sunlight exposure. Evidence in vitiligo concerns combination treatment with phototherapy; the six-person stroke study cannot establish treatment benefit or safety. Results from these different settings should not be pooled.1234
Reviewed study record
EPP: European placebo-controlled trial
Design
A randomized, double-blind, placebo-controlled trial followed pain-free sunlight exposure over nine months.1
Population
The abstract reports 74 participants with erythropoietic protoporphyria in the European trial.1
Outcomes reported
Median pain-free sunlight exposure was 6.0 hours with afamelanotide versus 0.8 hours with placebo over nine months. The report also counted 77 versus 146 phototoxic reactions.1
Limitations
Exposure measurements and follow-up differ from the US trial. The abstract summarizes safety across both trials, so its overall safety statement is not a separate European-trial estimate or proof about uncommon long-term harms.1
Reviewed study record
EPP: US placebo-controlled trial
Design
A randomized, double-blind, placebo-controlled trial followed pain-free sunlight exposure over six months.1
Population
The abstract reports 94 participants with erythropoietic protoporphyria in the US trial.1
Outcomes reported
Median pain-free sunlight exposure was 69.4 hours with afamelanotide versus 40.8 hours with placebo over six months.1
Limitations
Exposure measurements and follow-up differ from the European trial. The numeric exposure results should not be directly compared across trials. The abstract’s overall safety statement covers both studies.1
Reviewed study record
EPP: German post-authorization cohort
Design
An observational registry study evaluated treated patients without an untreated comparison group.2
Population
The report describes 200 patients with EPP in the German post-authorization safety study.2
Outcomes reported
Quality-of-life scores improved relative to baseline, and 91% continued treatment at the reported cutoff. The study also collected treatment-emergent adverse events.2
Limitations
Without an untreated comparator, changes cannot establish a causal treatment effect. Treatment continuation is not proof of safety, and treatment selection can introduce bias.2
Reviewed study record
Vitiligo: afamelanotide plus phototherapy
Design
A randomized multicenter study compared afamelanotide plus narrowband UV-B with phototherapy alone.3
Population
The study enrolled 55 adults with nonsegmental vitiligo and Fitzpatrick skin phototypes III–VI.3
Outcomes reported
The combination group had greater reported repigmentation at day 168. Erythema occurred in both groups; nausea and minor infections were reported in the combination group.3
Limitations
The study does not isolate afamelanotide without phototherapy or establish results in all skin phototypes. PubMed links subsequent correspondence about the study.3
Reviewed study record
Acute stroke: early feasibility study
Design
An open-label Phase 2a study assessed safety and exploratory recovery measures without a control group.4
Population
Six patients with acute ischemic stroke who were ineligible for revascularization therapies were enrolled.4
Outcomes reported
The surviving patients showed neurological improvement. One patient died after a recurrent stroke, which investigators assessed as unrelated to the study drug.4
Limitations
Six uncontrolled observations cannot distinguish drug effects from natural recovery or establish safety. The authors called for randomized studies.4
Reviewed source set
PubMed · 26132941Afamelanotide for Erythropoietic Protoporphyria. ↗PubMed PMID 26132941 · EFetch XML reviewed 2026-09-20 · payload SHA-256 b94a37b2a147aaedfdcff20011049a0589c73cd3790c0e727e5e8a209b2d802f
No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1056/nejmoa1411481. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/phpp.13012. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1001/jamadermatol.2014.1875. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1186/s12883-023-03338-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗